Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
Hirotsugu KenmotsuSeiji NihoMasahiro TsuboiMasashi WakabayashiGenichiro IshiiKazuo NakagawaHaruko DagaHiroshi TanakaHaruhiro SaitoKeiju AokageToshiaki TakahashiToshi MenjuTakashi KasaiIchiro YoshinoKoichi MinatoMorihito OkadaJunko EbaHisao AsamuraYuichiro OheShun-Ichi WatanabePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Irinotecan plus cisplatin is not superior to etoposide plus cisplatin for improving RFS in patients with completely resected HGNEC; thus, etoposide plus cisplatin remains the standard treatment.